Clinical Trial

Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC

Active, Not Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is one center, single-arm, open-label investigator initiated trial to assess the safety and efficacy of enhanced autologous PSMA chimeric antigen receptor T cells in the treatment for patients with refractory castration resistant prostate cancer, and the sample size is set to 7-18 subjects.
Protocol Amendment History 1 change
notable Primary completion pushed: 2026-05 -> 2026-08 2026-07-24
Trial Details
NCT Number NCT06228404
Lead Sponsor Shanghai Changzheng Hospital
Collaborators: Bioray Laboratories
Conditions Metastatic Castration-resistant Prostate Cancer, Castration-resistant Prostate Cancer
Enrollment 18 participants
Start Date 2024-03-03
Primary Completion 2026-08 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-23